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Abstract
Background: Urothelial carcinoma (UC) is characterized by nonrandom chromosomal aberrations, varying from one
or a few changes in early-stage and low-grade tumors, to highly rearranged karyotypes in muscle-invasive lesions. Recent
array-CGH analyses have shed further light on the genomic changes underlying the neoplastic development of UC, and
have facilitated the molecular delineation amplified and deleted regions to the level of specific candidate genes. In the
present investigation we combine detailed genomic information with expression information to identify putative target
genes for genomic amplifications.
Methods: We analyzed 38 urothelial carcinomas by whole-genome tiling resolution array-CGH and high density
expression profiling to identify putative target genes in common genomic amplifications. When necessary expression
profiling was complemented with Q-PCR of individual genes.
Results: Three genomic segments were frequently and exclusively amplified in high grade tumors; 1q23, 6p22 and 8q22,
respectively. Detailed mapping of the 1q23 segment showed a heterogeneous amplification pattern and no obvious
commonly amplified region. The 6p22 amplicon was defined by a 1.8 Mb core region present in all amplifications, flanked
both distally and proximally by segments amplified to a lesser extent. By combining genomic profiles with expression
profiles we could show that amplification of E2F3, CDKAL1, SOX4, and MBOAT1 as well as NUP153, AOF1, FAM8A1 and
DEK in 6p22 was associated with increased gene expression. Amplification of the 8q22 segment was primarily associated
with YWHAZ (14-3-3-zeta) and POLR2K over expression. The possible importance of the YWHA genes in the development
of urothelial carcinomas was supported by another recurrent amplicon paralogous to 8q22, in 2p25, where increased
copy numbers lead to enhanced expression of YWHAQ (14-3-3-theta). Homozygous deletions were identified at 10
different genomic locations, most frequently affecting CDKN2A/CDKN2B in 9p21 (32%). Notably, the latter occurred
mutually exclusive with 6p22 amplifications.
Conclusion: The presented data indicates 6p22 as a composite amplicon with more than one possible target gene. The
data also suggests that amplification of 6p22 and homozygous deletions of 9p21 may have complementary roles.
Furthermore, the analysis of paralogous regions that showed genomic amplification indicated altered expression of
YWHA (14-3-3) genes as important events in the development of UC.
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Background
Urothelial carcinoma (UC) is characterized by nonran-
dom chromosomal aberrations, varying from one or a few
changes in early-stage and low-grade tumors, to massively
rearranged karyotypes in muscle-invasive lesions [1].
Rearrangements of chromosome 9, resulting in loss of
chromosome 9 material, are the most common cytoge-
netic alterations and are seen in close to half of the cases.
Loss of material from chromosome arm 11p, and gains of
chromosome 7 and chromosome arm 1q seem to be early
but secondary changes. UC is also characterized by a
strong association between tumor stage/grade and karyo-
typic complexity, indicating that progressive accumula-
tion of genetic alterations is the driving force behind
multi-step bladder carcinogenesis [2]. Cytogenetic data
have been corroborated by comparative genomic hybridi-
zation (CGH) investigations [3-5], which in addition have
been valuable for identification of high-level amplifica-
tions. Recent array CGH analyses of bladder tumors [6,7]
and cell lines [8], based on non-tiling bacterial artificial
chromosome (BAC) arrays have shed further light on the
genomic changes underlying neoplastic development.
These studies have facilitated the molecular delineation of
additional amplified and deleted regions to the level of
specific candidate genes. Recurrent high-level local ampli-
fications have so far been reported in many genomic
regions, including 1q21-24, 3p22-24, 6p22, 8q21-22,
10p13-14, 11q13, 12q13-15, and 17q21 [3-8]. To provide
a more complete and detailed map of previously observed
amplified and deleted segments, and to identify new copy
number aberrations (CNAs) of importance to urothelial
tumorigenesis, we used whole-genome tiling-resolution
array CGH based on a 32 k BAC clone set to analyze 38
primary urothelial carcinomas. In order to allow a com-
prehensive analysis also of transcriptional effects of the
identified CNAs, the copy number analysis was comple-
mented with expression profiling using high-density (36
k) oligonucleotide micro arrays. With this approach we
present genomic borders and putative target genes for 9
recurrent amplifications, some of which specific for
advanced tumors, and for 7 previously not described
homozygous deletions, of which one is recurrent. We also
studied the pattern of CNA occurrence, and show that
6p22 amplifications are not independent of homozygous
deletions in 9p21, and that amplification of paralogous
segments in 8q22 and 2p25 appear to act complementary
and may have equivalent biological outcomes as they
both result in increased expression of members of the
YWHA genes, encoding 14-3-3 proteins.
Methods
Patients and tissue
Tumors were collected by cold-cup biopsies from the exo-
phytic part of the bladder in patients undergoing resection
at the University Hospital of Lund, Sweden, between 2001
and 2004 and kept at -80C until further use. Sample qual-
ity was evaluated by histology. Altogether 10 Ta, 9 T1, and
19 muscle-invasive (T2-T4) tumors were included in the
study. Of these 15 were low grade (grades G1 and G2) and
23 high grade (G3) tumors. Tumor pathology, based on
transurethral and cystectomy specimens, was assessed by
an experienced pathologist (GC) and is listed together
with other clinical data in Additional file 1. The investiga-
tion was approved by the local ethical committee at the
Lund University and a written consent was obtained from
all patients.
Nucleic acid isolation
DNA was isolated using the DNeasy Tissue Kit (Qiagen,
Valencia, CA), including the optional RNase H treatment,
and verified for high quality by agarose gel electrophore-
sis. Total RNA was extracted using Trizol reagent (Invitro-
gen, Carlsbad, CA). Isolated RNA was purified on Qiagen
RNeasy columns (Qiagen) and sample integrities were
assessed on an Agilent 2100 Bioanalyzer (Agilent technol-
ogies, Palo Alto, CA).
Microarray hybridizations
Labeling of test and reference DNA was performed as pre-
viously described [9], with slight modifications. In brief,
1.5 µg of tumor and male reference DNA was fluores-
cently labeled with Cy3-dCTP and Cy5-dCTP (Amersham
Biosciences, Uppsala, Sweden), respectively, using the
Array CGH labeling kit (Invitrogen, Carlsbad, CA), and
purified using filter-based spin columns (Cyscribe GFX
Purification kit, Amersham Biosciences). Differentially
labeled DNA was pooled, mixed with 100 µg Human Cot-
1 DNA (Invitrogen), and lyophilized prior to resuspen-
sion in 55 µl hybridization solution (50% formamide,
10% dextran sulfate, 2× SSC, 2% SDS, 10 µg/µl yeast
tRNA). Probes were heated at 70°C for 15 minutes and at
37°C for 30 minutes before hybridization to micro arrays
for 48-72 hours at 37°C. High-resolution tiling BAC
arrays produced at the Swegene DNA Micro Array
Resource Center, Department of Oncology, Lund Univer-
sity, Sweden [10] using the BAC Re-Array set Ver. 1.0
(32,433 BAC clones) previously described [11] was used.
The BAC Re-Array set was obtained from the BACPAC
Resource Center at Children's Hospital Oakland Research
Institute, Oakland (CA). Prior to hybridization, micro
arrays were UV-cross linked at 500 mJ/cm2 and pretreated
using the Universal Micro array Hybridization Kit (Corn-
ing, Acton, MA) according to the manufacturer's instruc-
tions. Slides were washed and scanned as previously
described [12]. Oligonucleotide arrays printed with 70-
mers from the OPERON v 3.0 set were obtained from the
Swegene DNA micro array resource centre [10]. The
36,288 oligonucleotides printed on each slide correspond
to 18,466 unique Entrez genes. Sample and Universal
Human Reference RNA (Stratagene, La Jolla, CA) labeling,BMC Medical Genomics 2008, 1:3 http://www.biomedcentral.com/1755-8794/1/3
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and micro array hybridization was performed using the
Pronto Plus System (Promega, Madison, WI; Coring,
Acton, MA) according to the manufacturer's specification.
Arrays were scanned with an Agilent G2565AA micro
array scanner (Agilent technologies).
Microarray image and data processing
Primary data were collected using the GenePix Pro 4.0
software (Axon Instruments Inc., Foster City, CA), and
raw result files were deposited into the web-based data-
base BioArray Software Environment (BASE) [13]. For
genomic profiling, spots were background-corrected using
the median foreground minus the median background
signal intensities for both dyes, and log2 ratios were calcu-
lated. Unreliable features, marked in the feature extraction
software, and spots not showing signal-to-noise ratios ≥ 3,
for both channels, were removed. Data normalization was
performed per array subgrid using Lowess curve fitting
[14] with a smoothing factor of 0.33. Chromosomes X
and Y BAC clones were omitted during the estimation of
the normalization function. The BASE implementation of
CGH-Plotter [15] was used to produce imbalance fre-
quency plots in which BACs were defined as gained, nor-
mal, or lost using gain/loss log2 ratio thresholds of ± 0.25,
and a moving mean sliding window of five clones. For
amplification frequency plots, amplifications were
defined as regions with at least two consecutive BAC
clones showing log2 ratios  ≥ 1.0. Amplicon sizes were
defined as the longest distance between the two outer-
most amplified BAC clones. In cases of highly discontinu-
ous amplification, amplicons were considered ended
when separated by at least two BAC clones with log2 ratios
below 0.5. Homozygous deletions were defined as regions
with consistent log2 ratios below -1.2, and with at least
one BAC showing a log2 ratio < -1.5. Mapping data were
obtained from the UCSC genome browser [16]. To iden-
tify genomic amplifications specific for G3 tumors a sig-
nificance analysis of micro arrays (SAM) was performed
[17]. Selection of amplification target genes was based on
three criteria. Potential target genes should ideally display
i) top ranking expression levels in cases with highest DNA
copy number of that particular gene, ii) a high Spearman
rank correlation throughout the entire data set, and iii) at
least 2-fold up regulation when amplified compared to
median expression of that gene in the data set.
Real-time quantitative RT-PCR analysis and genomic PCR 
analysis
Custom-made TaqMan probes for the test genes and for
three internal standards (ACTB, HPRT1, and RPLP0) were
obtained from Applied Biosystems (Foster City, CA.), and
reactions performed on a Real Time PCR System 7500
(Applied Biosystems) according to the manufacturer's rec-
ommendations. To verify potential homozygous dele-
tions sequence-tagged site (STS) markers within the
deleted regions were used for semi-quantitative genomic
PCR analysis. Quantification of PCR products were per-
formed as previously described [18].
Results
Results from the genome-wide DNA copy number analy-
ses of the 38 tumors are shown in Figure 1A (the complete
data set is available in Additional file 2). Low and
medium grade (G1/G2) tumors generally contained few
changes (Figure 1B), paralleled by similar low level of
complexity in Ta tumors (Table 1). T1 tumors showed
increased frequencies of genomic imbalances, and T2-T4
tumors showed even more complex aberrations with as
many as 24 different frequent (> 30%) imbalances. Losses
and homozygous deletions were seen at similar frequen-
cies in low/medium and high grade tumors, whereas gains
and particularly amplifications were considerably more
frequent in G3 tumors (Figure 2); high grade tumors on
average showed more than 10 times the number of ampli-
fications as low/medium grade tumors (4.2 vs. 0.3). The
most frequent amplifications were localized to 6p22 (8
cases) and 8q22 (5 cases), respectively, both observed
exclusively in high-grade tumors. Because only one of the
tumors showed co-occurrence of the two events, at least
one of these aberrations were present in more than 50%
of the G3 tumors (12 of 23 cases).
Apart from the two major targets mentioned above, seven
additional segments showed recurrent (≥ 3 cases) overlap-
ping amplifications; 1p34, 1q23, 2p25, 3p25, 10q22,
11q13, and 16p13 (Table 2). The most common of these,
1q23, spanned a 5.4 Mb region with a commonly ampli-
fied segment of 0.8 Mb. The genomic profiles of the indi-
vidual cases were very diverse e.g., case 27, with the largest
amplification showed the highest amplifications levels in
a region 1.2 Mb proximal to the commonly amplified seg-
ment, whereas case 28 showed peak log2 ratios on the dis-
tal side. These findings indicate that 1q23 amplifications
are heterogeneous and may represent different genomic
events with no common target region. Putative target
genes in the other recurrent core amplicons are listed in
Table 2. The 11q13 amplification, including CCND1, was
the only genomic amplification that was recurrent in G1/
G2 tumors. A statistical analysis (SAM) confirmed that
local amplification of 1q23, 6p22, and 8q22 were signifi-
cant discriminators between G1/G2 and G3 tumors (data
not shown).
The 6p22 amplicon
Genomic amplification in 6p22 was seen in 8 cases. To
identify the critical region, BAC clones in the region were
classified as amplified or unamplified in all 23 G3 tumors
and the amplification frequencies plotted (Figure 3). This
delineated a complex 1.8 Mb core amplicon, present in 7-
8 (30-35%) of the high grade tumors, and encompassingBMC Medical Genomics 2008, 1:3 http://www.biomedcentral.com/1755-8794/1/3
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A. Genome-wide overview of copy number alterations in 38 bladder tumors Figure 1
A. Genome-wide overview of copy number alterations in 38 bladder tumors. Each row represents a separate tumor sample, 
with case numbers and tumor grades indicated to the left. Each column shows one of the 32,433 different BAC clones on the 
microarray, ordered from 1pter to Yqter. Test over reference fluorescence ratios (moving average, symmetric 4-nearest 
neighbors) based on a log2 pseudocolor scale (indicated) are shown. B. Genome-wide imbalance frequency plot for G1/G2 and 
G3 tumors. Gains and losses are as defined in materials and methods. Red, gains; green, losses.BMC Medical Genomics 2008, 1:3 http://www.biomedcentral.com/1755-8794/1/3
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four genes; MBOAT1, E2F3, CDKAL1, and SOX4. Interest-
ingly, only CDKAL1 was localized in the region shared by
all 8 cases, although some of the proximal exons of the
gene extended outside the amplification border in one of
the tumors. The core region was flanked by sequences
amplified in 5-6 (22-26%) of the high grade tumors; one
distal that included ID4, and one proximal that included
PRL and HDGFL1 (Figure 3). A 2 Mb segment amplified
in three (13%) of the high grade cases was located further
distally. Because of the high gene content in this region
this latter segment was included in the overall expression
analysis of the region. Altogether, expression profiling
data were available for 9 of the 16 annotated genes in the
commonly amplified segment; CAP2, FAM8A1, NUP153,
KIF13A, TPMT, AOF1, DEK, MBOAT1and SOX4.
NUP153  and  FAM8A1  showed a strong association
between gene expression and gene copy numbers (Addi-
tional file 3). No BAC clones corresponding to the genes
TPMT, AOF1 and DEK were available after the final filtra-
tion of the BAC array data, however, both AOF1 and DEK
showed substantial correlations between gene expression
and gene copy numbers as estimated by BAC clones flank-
ing the genes. The tumors that showed the highest gene
copy numbers for NUP153, AOF1 and DEK were also the
top ranking cases with regard to expression. In the core
amplicon six and four of the seven cases with SOX4 and
MBOAT1 amplifications, respectively, were top ranking
with respect to expression. Because no microarray expres-
sion data were available for three of the most commonly
amplified genes, E2F3, CDKAL1 and ID4, these were ana-
lyzed separately by real-time quantitative PCR. This anal-
ysis showed a moderate copy number dependent
expression for ID4 but a strong association between the
DNA and mRNA levels for CDKAL1 and E2F3 (Additional
file 4). Hence, a strong link between gene copy numbers
and gene expression is seen for the frequently amplified
genes MBOAT1, E2F3, CDKAL1, and SOX4 as well as for
the less frequently amplified NUP153, AOF1, FAM8A1,
and DEK.
The 8q22 and the related 2p25 amplicon
The core amplicon in 8q22 extended over a 1.8 Mb region
and included 10 annotated genes (Figure 4), of which
expression data were available for five, POLR2K, RNF19,
PABPC1, YWHAZ, and NCALD (Additional file 3). For
Average number of gains, losses, amplifications and  homozygous losses in G1/G2 and G3 tumors, respectively Figure 2
Average number of gains, losses, amplifications and 
homozygous losses in G1/G2 and G3 tumors, respectively.
Table 1: Genomic imbalances categorized according to grade and stagea, b
G1/G2 G3 Ta T1 ≥ T2
Gains Losses Gains Losses Gains Losses Gains Losses Gains Losses
+1q -9 +1qprox 5qprox-+ 1 q 9 p - + 1 q prox 6qdist-+ 1 q prox 2qdist-
+5pdist 11pint-+ 2 p prox 6q- 9q- +5p 8p- +2pdist 5qprox-
17pdist-+ 3 p prox 8p- +8qprox 9q- +3pdist 6q-
19p- +3pdist 9pint-+ 8 q dist 11p- +5p 8p-
+5p 9qdist- +10p 17p- +6pint 9p-
+6pint 11pint-+ 1 3 1 9 p - + 8 q int 9q-
+8qint 17p- +15qdist 22q- +8qdist 11p-
+8qdist -22 +18p +10p 17p-
+10pdist +21q +13qprox 22q-
+13pprox +13qdist
+13qdist +16q
+16q +17q
+20 +19qprox
+21q +20
+21q
aImbalances seen in ≥ 30% of the cases
bprox, proximal part of chromosome arm; int, interstitial part of chromosome arm; dist, distal part of chromosome arm.BMC Medical Genomics 2008, 1:3 http://www.biomedcentral.com/1755-8794/1/3
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two of these, POLR2K  and  YWHAZ  (14-3-3-zeta), the
tumors with highest copy numbers also showed the high-
est expression. Furthermore, these genes showed Spear-
man rank correlations of 0.77 and 0.68, respectively,
between gene expression and gene copy numbers suggest-
ing a strong link between POLR2K and YWHAZ gene copy
numbers and expression. Three additional tumor cases, all
G3 tumors, shared a 1 Mb amplified region in 2p25
(Additional file 3). A comprehensive analysis revealed
that this segment contained several genes paralogous to
genes in the 8q22 amplicon; YWHAZ, GRHL2, NCALD,
RRM2B, and KLF10  in 8q22 showed the related genes
YWHAQ  (14-3-3-theta),  GRHL1,  HPCAL1,  RRM2, and
KLF11 in the 2p25 amplicon. Among the 13 genes in the
2p25 amplicon for which expression data were available,
six genes showed top ranking expression levels when
amplified, ITGB1BP1, CPSF3, ADAM17, YWHAQ, TAF1B
and RRM2. Hence, the common denominator between
the 8q22 and the 2p25 amplicons is the increase in
expression of the 14-3-3-genes. Intriguingly, none of the
cases with 8q22 amplifications showed concurrent ampli-
fication of 2p25. The seemingly complementing 8q22 and
2p25 amplifications were thus seen in the same frequency
as the 6p22 amplifications.
Homozygous deletions
The array CGH analysis indicated homozygous deletion
in ten different genomic locations of which six were veri-
fied by semi-quantitative Q-PCR (Additional file 5). The
most frequent was observed in 9p21, detected in 12
(32%) of the cases (Figure 5A). These deletions included
the CDKN2A (p14ARF), CDKN2B, and MTAP loci in all
cases and spanned a 4 Mb region, mainly extending at the
proximal side of the CDKN2A/CDKN2B  loci. The fre-
quency of 9p21 homozygous deletion did not differ
between G1/G2 and G3 cases (χ2, p > 0.05). Interestingly,
homozygous loss of the CDK2A/CDK2B  locus was not
seen in cases with 6p22 amplifications, indicating that
these changes are not independent events (p = 0.017,
Fishers exact test). Homozygous deletions were detected
in five additional locations on chromosome 9; in 9p24,
9p23, 9q21, 9q22, and in 9q33 respectively, of which the
9q22 deletion was detected in two cases. Case 3 was
exceptional as this tumor showed three different
homozygous deletions on chromosome 9, in 9p23, 9p21
and in 9q21 (Figure 5B). Additional homozygous dele-
tions were detected in 4q35, 10q26, 13q14, and 21q21, of
which only one covered a known tumor suppressor gene,
RB1 in 13q14.
Discussion
We performed whole-genome tiling-resolution array CGH
analyses to characterize gene copy number aberrations in
38 cases of urothelial carcinomas. To make a comprehen-
sive evaluation of the consequences at the expression level
the array CGH data was compared with expression data
obtained by high density expression profiling. Low grade
and early stage tumors showed a limited number of
genomic imbalances with gain of 1q and loss of chromo-
some 9q as the most frequent changes. T1 tumors har-
bored additional changes and frequently showed losses of
6q, 8p, 9q, 11p, 17p, 19p, and 22q, and gains of 1q, 5p,
8q, 10p, and 13, and 5p. Late-stage tumors, T2-T4,
showed several additional genomic imbalances and
showed complex genomic changes. A major difference
was seen between G1/G2 and G3 tumors with regard to
gains and amplifications. Gains were more frequent in G3
tumors and amplifications more than 10 times as fre-
quent in high grade than in low/medium grade tumors.
This is in line with the recent finding that high grade
tumors show frequent anaphase bridges that ultimately
may lead to breakage-fusion-bridge cycles producing
genomic amplifications [19]. In contrast to Blaveri et al.
[7], we did not see a reduction in the number of affected
regions in late-stage tumors. Instead T2-T4 tumors
showed considerably more complex changes than Ta/T1
Table 2: Summary of common recurrently amplified regionsa, b
Cytogenetic 
region
Mb start position 
(BAC)
Mb end position 
(BAC)
Size (Mb) Genesc No. cases
1p34 39.27 (RP11-528I12) 40.26 (RP11-747C18) 1.0 MACF1, PABPC4, TRIT1 3 (8%)
1q23 157.00 (RP11-735D24) 157.81 (RP11-812N5) 0.8 - 4 (11%)
2p25 9.42 (RP11-360P14) 10.34 (RP11-360P14) 0.9 3 (8%)
3p25 10.20 (RP13-635L13) 12.52 (RP11-738A2) 2.3 TATDN2, SEC13L1, VGLL4 3 (8%)
6p22 20.07 (RP11-345F7) 22.08 (RP11-630B10) 1.8 8 (21%)
8q22 101.23 (RP11-321E7) 102.99 (RP11-811I18) 1.8 5 (13%)
10q22 76.24 (RP11-368I19) 78.49 (RP11-272P2) 2.3 MYST4 3 (8%)
11q13 69.07 (CTD-2192B11) 70.20 (CTD-2011L13) 1.1 CCND1, ORAOV1, PPFIA1, CTTN 3 (8%)
16p13 10.59 (RP11-78D17) 12.84 (RP11-310B24) 2.3 NUBP1, DEXI, TXNDC11, ZC3H7A, RSL1D1, GSPT1 3 (8%)
aMapping data is based on the UCSC genome browser (May 2004 freeze), and listed regions represent core amplicons.
bOnly regions amplified in at least 3 cases are listed.
cGenes that showed top ranking expression levels when genomically amplified. More detailed data for the 6p22, 8q22, and for 2p25 is given in 
Additional file 3.BMC Medical Genomics 2008, 1:3 http://www.biomedcentral.com/1755-8794/1/3
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tumors, corresponding to previous cytogenetic and con-
ventional CGH results that have shown a larger number of
genomic alterations in high-grade and late-stage tumors
[2-4,20].
The analysis showed that amplifications of 1q23 were
highly heterogeneous. Individual cases showed extended
amplicons with peak copy number ratios in different areas
and with no obvious commonly amplified segment. Gain
of chromosome arm 1q is frequent in UC [1,2] and local
amplifications in 1q23 have previously been reported in
studies using conventional CGH [3,5]. However, due to
limited resolution in traditional CGH analysis diverse
amplifications within a 5 Mb genomic region may have
been interpreted as a common genomic event and hence
assumed to target the same genomic segment. Interest-
ingly, the present tiling resolution analysis indicates that
this is most likely not the case. There are at least two pos-
sible explanations for these findings; either the 1q23
region harbors more than one target segment, or the 1q23
region show local genomic instability resulting in fre-
quent gains or high level amplifications. Both situations
would result in a heterogeneous pattern of changes.
The most frequently amplified chromosomal segment
was 6p22. This segment has been repeatedly shown to be
amplified in UC and to cover the genes E2F3, CDKAL1,
and SOX4 [6,8,21-25]. In the present investigation a 1.8
Mb core region, included in 88-100% of the cases with
6p22 amplifications, was defined. This region contains
MBOAT1, E2F3, CDKAL1, and SOX4. The core segment
was flanked by two regions included in 38-75% of the
amplifications that on the distal side contained ID4, and
on the proximal side PRL and HDGFL1. A further distally
located region, present in three (38%) of the cases with
amplification, contained ten additional genes. In total a
more than 6 Mb region was found to be repeatedly
included in the 6p22 amplifications. To identify possible
targets genes within this segment we used different criteria
based on available expression data. Six genes; NUP153,
AOF1, DEK, SOX4, FAM8A1, and MBOAT1 showed top
ranking expression levels when amplified. By Q-PCR we
also established a strong association between E2F3 and
CDKAL1 gene expression and gene copy numbers. This
identifies eight possible candidate genes in 6p22 that may
be ranked according the frequency by which they take part
in 6p22 amplifications as CDKAL1, E2F3, and SOX4 >
MBOAT1 > DEK, NUP153, FAM8A1, and AOF1.
Several investigations have shown a strong association
between gene copy numbers and gene expression for E2F3
and CDKAL1 [8,21,22]. In two recent studies knock down
experiments of E2F3 in bladder cancer cells lines with 6p
amplification was shown to strongly reduce cellular pro-
liferation whereas a similar knock down of CDKAL1 did
not have this effect [26,27]. This indicates E2F3 as a major
target for the 6p22 amplification. The E2F3  locus pro-
duces two alternative proteins, E2F3a and E2F3b [28].
E2F3a is an inducible activator of cell cycle progression
whereas E2F3b is constitutively expressed and functions
as a negative regulator of p14ARF expression, thereby com-
promising TP53 activity [29]. Genomic amplification of
the  E2F3  locus may consequently contribute to tumor
development both by accelerating the cell cycle and by
raising the threshold for apoptosis via inactivation of
p14ARF. In this context it is worth noting that none of the
cases with 6p amplification showed homozygous dele-
tions leading to loss of p14ARF. Hence, amplification of 6p
and homozygous deletion of the CDKN2A/CDKN2B
locus behaves as complementary events; one leading to
the simultaneous loss of CDKN2A, a cell cycle inhibitor,
and p14ARF activity, and a second to increased E2F3, a cell
cycle activator, and reduced p14ARF activity. As a conse-
quence 65% of the G3 tumors may show impaired p14ARF
function.
SOX4 belongs to the SRY-related HMG-box (SOX) family
of transcription factors involved in the regulation of
embryonic development and in cell fate determination.
The protein acts as a transcriptional regulator in the apop-
tosis pathway as well as in pathways leading to tumori-
genesis. SOX4 is over expressed in several tumor types
[30] and was found to be significantly over expressed in
bladder tumors in a recent investigation [31], suggesting a
role for SOX4  in bladder cancer development. Intrigu-
ingly, both experimentally increased [31] and decreased
[32]SOX4 expression induces an apoptotic response. This
may indicate that SOX4 expression has to be finely tuned
not to induce deleterious cellular responses and may,
partly, explain why no consistent correlation between
SOX4 amplification and expression has been seen in pre-
vious investigations [8,21,31].
The MBOAT1, DEK, FAM8A, AOF1, and NUP153 genes
were amplified at lower frequencies than E2F3. Of these
DEK, a chromatin-associated protein could provide a
selective advantage when amplified as DEK function as an
inhibitor of senescence [33]. Furthermore, as DEK  is
under the transcriptional control of E2F3 [34] co-amplifi-
cation of DEK with E2F3 may enhance DEK expression
further. NUP153 plays an important role in nuclear pore
function and have key functions in both import and
export to the nucleus. NUP153 is known to affect the sub
cellular distribution of transcription factor such as
SMAD2, STAT1, and PU.1 [35], hence, altered NUP153
expression may modify the accessibility of key regulatory
proteins. The possible roles of MBOAT1, FAM8A1, and
AOF1  in carcinogenesis are, however, less clear. Taken
together, the present comprehensive analysis of 6p22
amplification in UC indicates that SOX4,  DEK  andBMC Medical Genomics 2008, 1:3 http://www.biomedcentral.com/1755-8794/1/3
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NUP153 may contribute to cellular transformation when
co-amplified with E2F3, and hence that 6p22 may repre-
sent a composite amplicon with more than one potential
target gene.
The core amplicon in 8q22 extended over a 1.8 Mb region
and included 8 annotated genes of which YWHAZ (14-3-
3-zeta) and POLR2K showed a strong association between
gene copy number and gene expression. Interestingly,
three tumors with no amplification of 8q22 showed
amplification of a 1 Mb paralogous region in 2p25. This
segment included several genes similar to genes within the
8q22 segment, such as YWHAQ, GRLH1,HCAL1, RRM2,
and KLF11. Two of the paralogous genes within the 2p25
amplicon showed a strong association between gene copy
numbers and gene expression, YWHAQ  (14-3-3-theta)
and RRM2. Hence, the common denominator of the 8q22
and 2p25 amplicons is the amplification and over expres-
sion of the paralogous 14-3-3-zeta and 14-3-3-theta genes.
Furthermore, if amplification of the YWHA genes may
substitute for each other, amplification of these genes is as
common as amplification of E2F3.
There are seven 14-3-3 isoforms described in mammals
[36]. The proteins are widely expressed and bind as dim-
ers to client proteins thereby modulating their enzymatic
activity, sub cellular localization, or potential to form pro-
tein complexes; more than 200 proteins have been
reported to associate with these proteins. It is believed that
14-3-3 proteins functions as general survival factors by
enhancing pro-survival signaling and suppressing pro-
apoptotic proteins [36]. The findings that 14-3-3-zeta and
-theta show increased expression in oral squamous cell
carcinomas and lung, stomach, and breast cancers [37-
40], and that mice transgenic for 14-3-3-zeta develop var-
ious types of tumours at young age [41] favors the conclu-
sion that 14-3-3-zeta and -theta may act as oncogenes also
in urothelial carcinomas.
Homozygous deletions were detected in six locations on
chromosome 9 and in four locations in the remaining
Amplification frequencies in 6p22 among all 23 high-grade tumors Figure 3
Amplification frequencies in 6p22 among all 23 high-grade tumors. The BAC clones (grey-filled circles) and the genes in the 
upper part of the graph are positioned/depicted according to their genomic position. The grey square in the ideogram (on top) 
illustrates the region on chromosome 6 included in the plot.BMC Medical Genomics 2008, 1:3 http://www.biomedcentral.com/1755-8794/1/3
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genome; 4q35, 10q23, 13q14, and 21q21. None of the
observed deletions coincides with deletions frequently
seen in cell lines [42] and only one, 9p21, has previously
been reported for urothelial carcinomas. Among the dele-
tions not occurring on chromosome 9 three, 4q35, 10q23,
and 21q21 respectively, extended over genes not previ-
ously associated with tumor development and may merit
further analyses. The 13q14 deletion, on the other hand,
affected the known tumor suppressor gene RB1, and
hence most likely has a pathological effect. As expected
the most frequent homozygous deletions occurred at
9p21, in a 4 Mb segment that consistently included
CDKN2A  and  CDKN2B. The observed frequency of
CDKN2A homozygous deletions reached 32%, which is
close to the frequency found by Q-PCR of micro dissected
tumor biopsies [43]. The deletions were more extensive
on the proximal than on the distal side of CDKN2A which
may be caused by the fact that the proximal region is less
dense with genes. An intriguing finding was the clustering
of homozygous deletions to chromosome 9.
Homozygous deletions were seen in five chromosome 9
locations, excluding the high-frequency CDKN2A region,
compared with a total of four homozygous deletions on
other chromosomes. Furthermore, one case showed two
homozygous deletions, and another case one
homozygous deletion in addition to a 9p21 deletion. This
high frequency of homozygous deletions is astonishing
but is in agreement with the high frequency of LOH and
chromosomal 9 losses seen in UC [44]. The accumulated
data reveals no specific pattern of LOH, which has led to
the suggestion that most of the LOH seen in chromosome
9 may be caused by unspecific mitotic recombination
[45]. A possible mechanism for the frequent homozygous
deletions could consequently be unequal mitotic recom-
bination events. Such events would produce homozygous
deletions after segregation of the recombined homo-
logues, as well as segmental duplications. Indeed, possi-
ble segmental duplications on chromosome 9 were seen
in a limited number of cases. Irrespective of the mecha-
nisms causing the deletions, the high frequency of
homozygous deletions at various locations on chromo-
some 9 point to the possibility that these deletions may
Amplification frequencies in 8q22 among all 23 high-grade tumors Figure 4
Amplification frequencies in 8q22 among all 23 high-grade tumors. The BAC clones (grey-filled circles) and the genes in the 
upper part of the graph are positioned/depicted according to their genomic position. The grey square in the ideogram (on top) 
illustrates the region on chromosome 8 included in the plot.BMC Medical Genomics 2008, 1:3 http://www.biomedcentral.com/1755-8794/1/3
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have a different origin and cellular consequence than the
more frequent 9p21 homozygous deletions.
Conclusion
The presented data indicates 6p22 as a composite ampli-
con with more than one possible target gene and suggests
that amplification of 6p22 and homozygous deletions of
9p21 may have complementary roles. The combined data
for amplified 8q22 and 2p25 paralogous genomic seg-
ments indicated that alterations of YWHA (14-3-3) genes
may be important in the development of urothelial carci-
nomas. Furthermore, chromosome 9 show an exception-
ally high frequency of homozygous deletions compared
to other chromosomes.
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